Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Sulfonimidamide analogs of oncolytic sulfonylureas.

Toth JE, Grindey GB, Ehlhardt WJ, Ray JE, Boder GB, Bewley JR, Klingerman KK, Gates SB, Rinzel SM, Schultz RM, Weir LC, Worzalla JF.

J Med Chem. 1997 Mar 14;40(6):1018-25.

PMID:
9083492
2.

Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts.

Gates SB, Worzalla JF, Shih C, Grindey GB, Mendelsohn LG.

Biochem Pharmacol. 1996 Nov 8;52(9):1477-9.

PMID:
8937460
3.

Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression.

Gates SB, Mendelsohn LG, Shackelford KA, Habeck LL, Kursar JD, Gossett LS, Worzalla JF, Shih C, Grindey GB.

Clin Cancer Res. 1996 Jul;2(7):1135-41.

4.

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.

Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB.

Cancer Res. 1996 May 15;56(10):2331-5.

5.

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.

Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG, Tanzer LR, Boder GB, Grindey GB.

Invest New Drugs. 1996;14(3):243-7.

PMID:
8958178
6.

The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.

Mendelsohn LG, Gates SB, Habeck LL, Shackelford KA, Worzalla J, Shih C, Grindey GB.

Adv Enzyme Regul. 1996;36:365-81.

PMID:
8869756
7.

Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias.

Waud WR, Gilbert KS, Grindey GB, Worzalla JF.

Cancer Chemother Pharmacol. 1996;38(2):178-80.

PMID:
8616909
8.

Medicinal chemistry of difluoropurines.

Andis SL, Bewley JR, Boder GB, Burke T, Dudley DE, Eichelberger LE, Grossman CS, Grindey GB, Hertel LW, Jordan CL, et al.

Semin Oncol. 1995 Aug;22(4 Suppl 11):54-60.

PMID:
7481846
9.

In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.

Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G.

Anticancer Res. 1995 Jul-Aug;15(4):1135-9.

PMID:
7653991
10.
12.

Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.

Schultz RM, Andis SL, Shackelford KA, Gates SB, Ratnam M, Mendelsohn LG, Shih C, Grindey GB.

Oncol Res. 1995;7(2):97-102.

PMID:
7579732
13.
14.

Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity.

Schmitz JC, Grindey GB, Schultz RM, Priest DG.

Biochem Pharmacol. 1994 Jul 19;48(2):319-25.

PMID:
8053927
15.

Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.

Brown TD, O'Rourke TJ, Kuhn JG, Craig JB, Havlin K, Burris HA 3rd, Cagnola J, Hamilton JM, Grindey GB, Satterlee WG, et al.

Anticancer Drugs. 1994 Apr;5(2):151-9.

PMID:
8049498
16.

A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.

Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB, Mendelsohn LG.

Cancer Res. 1994 Feb 15;54(4):1021-6.

PMID:
8313357
17.

Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.

Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Grindey GB, Bonjouklian R.

Cancer Chemother Pharmacol. 1994;34(4):344-50.

PMID:
8033301
18.

Effect of albumin on antitumor activity of diarylsulfonylureas.

Schultz RM, Andis SL, Toth JE, Boder GB, Rinzel SM, Grindey GB.

Anticancer Res. 1993 Nov-Dec;13(6A):1939-43.

PMID:
8297099
19.

Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).

Dolan ME, Pegg AE, Moschel RC, Grindey GB.

Biochem Pharmacol. 1993 Jul 20;46(2):285-90.

PMID:
8347150
20.

Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.

Ehlhardt WJ, Sullivan HR, Wood PG, Woodland JM, Hamilton M, Hamilton C, Cornpropst D, Grindey GB, Worzalla JF, Bewley JR, et al.

J Pharm Sci. 1993 Jul;82(7):683-8.

PMID:
8360840
21.

Synthesis and antitumor activity of LY288601, the 5,6-dihydro analog of LY231514.

Barnett CJ, Wilson TM, Grindey GB.

Adv Exp Med Biol. 1993;338:409-12. No abstract available.

PMID:
8304146
22.

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB.

Oncol Res. 1993;5(6-7):223-8.

PMID:
8123942
23.

Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.

Taylor CW, Alberts DS, Peng YM, McCloskey TM, Matzner M, Roe DJ, Plezia PM, Grindey GB, Hamilton M, Seitz D.

J Natl Cancer Inst. 1992 Dec 2;84(23):1798-802.

PMID:
1433369
24.
25.

Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas.

Ehlhardt WJ, Woodland JM, Worzalla JF, Bewley JR, Grindey GB, Todd GC, Toth JE, Howbert JJ.

Chem Res Toxicol. 1992 Sep-Oct;5(5):667-73.

PMID:
1446007
26.

Sulfonylureas: a new class of cancer chemotherapeutic agents.

Mohamadi F, Spees MM, Grindey GB.

J Med Chem. 1992 Aug 7;35(16):3012-6.

PMID:
1501228
27.

Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD.

Anticancer Drugs. 1992 Apr;3(2):143-6.

PMID:
1525392
28.

Synthesis and biological activity of acyclic analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid.

Shih C, Gossett LS, Worzalla JF, Rinzel SM, Grindey GB, Harrington PM, Taylor EC.

J Med Chem. 1992 Mar 20;35(6):1109-16.

PMID:
1552503
29.

Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W.

Cancer Res. 1992 Feb 1;52(3):533-9.

30.
31.

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W.

Cancer Res. 1991 Nov 15;51(22):6110-7.

32.
33.

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W.

Mol Pharmacol. 1990 Oct;38(4):567-72.

PMID:
2233693
34.

Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer.

Worzalla JF, Bewley JR, Grindey GB.

Invest New Drugs. 1990 Aug;8(3):241-51.

PMID:
2272765
35.

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB.

Cancer Res. 1990 Jul 15;50(14):4417-22.

36.

Current status of cancer drug development: failure or limited success?

Grindey GB.

Cancer Cells. 1990 Jun;2(6):163-71. Review.

PMID:
2201343
37.

Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea.

Houghton PJ, Bailey FC, Germain GS, Grindey GB, Howbert JJ, Houghton JA.

Biochem Pharmacol. 1990 Apr 1;39(7):1187-92.

PMID:
2322303
38.

Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells.

Houghton PJ, Bailey FC, Houghton JA, Murti KG, Howbert JJ, Grindey GB.

Cancer Res. 1990 Feb 1;50(3):664-8.

39.

N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells.

Houghton PJ, Bailey FC, Germain GS, Grindey GB, Witt BC, Houghton JA.

Cancer Res. 1990 Jan 15;50(2):318-22.

PMID:
2295071
40.

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine).

Grindey GB, Hertel LW, Plunkett W.

Cancer Invest. 1990;8(2):313. No abstract available.

PMID:
2400957
41.

Vinca alkaloids.

Grindey GB.

Curr Opin Oncol. 1989 Dec;1(2):203-5. Review. No abstract available.

PMID:
2489961
42.

Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.

Taylor EC, Hamby JM, Shih C, Grindey GB, Rinzel SM, Beardsley GP, Moran RG.

J Med Chem. 1989 Jul;32(7):1517-22.

PMID:
2738886
43.

Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.

Houghton PJ, Houghton JA, Myers L, Cheshire P, Howbert JJ, Grindey GB.

Cancer Chemother Pharmacol. 1989;25(2):84-8.

PMID:
2598403
44.
45.
46.

Studies of the antitumor activity of (2-alkoxyalkyl)- and (2-alkoxyalkenyl)phosphocholines.

Bonjouklian R, Phillips ML, Kuhler KM, Grindey GB, Poore GA, Schultz RM, Altom MG.

J Med Chem. 1986 Dec;29(12):2472-7.

PMID:
3783607
47.

Biochemical and antitumor effects of the combination of thymidine and 1-beta-D-arabinofuranosylcytosine against leukemia L1210.

Kinahan JJ, Kowal EP, Grindey GB.

Cancer Res. 1981 Feb;41(2):445-51. No abstract available.

48.

Antitumor activity of cytidine dialdehyde and its effects on nucleotide and nucleic acid synthesis.

Kinahan JJ, Pavelic ZP, Leonard RJ, Bloch A, Grindey GB.

Cancer Res. 1980 Mar;40(3):598-603.

49.

Inhibition of calf thymus DNA polymerase-alpha by deoxyribonucleoside triphosphates.

Grindey GB, Winkler M, Otten M, Steinberg JA.

Mol Pharmacol. 1980 Mar;17(2):256-61. No abstract available.

PMID:
7393207
50.

Isolation of a DNA polymerase alpha-associated regulatory protein from calf thymus.

Steinberg JA, Otten M, Grindey GB.

Cancer Res. 1979 Nov;39(11):4330-5.

Supplemental Content

Loading ...
Support Center